Powerful progress
Veeva’s predictions for the life sciences industry in 2021
While COVID-19 undoubtedly brought great chaos and crises last year, it also fuelled incredible innovation and collaboration across the life sciences industry. Looking ahead, the industry is showing no signs of slowing down – and digital will be key in making that happen. As companies continue opening digital channels to accelerate commercial and drug development, we’ll see new operating models reshape the industry and drive powerful transformation for years to come. Here are Veeva’s top life sciences predictions for 2021, from our panel of industry experts.
1. Unified systems will allow for sustained innovation in the industry
Veeva Systems converts to a public benefit corporation While the change signifies the life-sciences solutions firm’s commitment to help customers and patients, day-to-day functions will remain much the same.
After 99% of voting shareholders voiced their support, Veeva systems has elected to become the first publicly traded company (as well as the largest company to date) to convert to a public benefit corporation (PBC). The move, effective February 1, means the firm remains a for-profit entity but will be legally responsible to balance the interests of customers, employees, partners and shareholders.
Additionally, Veeva will expand its certificate of incorporation to include a public benefit purpose, “to help make the industries it serves more productive and create high-quality employment opportunities.”